BRIVATIME 50

Description

BRIVATIME 50 contains Brivaracetam, a next-generation antiepileptic drug (AED) used for the treatment of partial-onset seizures in patients with epilepsy. It works by binding to synaptic vesicle protein 2A (SV2A) in the brain, which modulates neurotransmitter release and helps stabilize electrical activity. BRIVATIME 50 offers rapid onset of action, strong seizure control, and improved tolerability compared to older AEDs.

This medication is suitable as both monotherapy and adjunctive therapy in adolescents and adults. It provides consistent and reliable seizure control with a lower risk of neuropsychiatric side effects. BRIVATIME 50 improves the patient’s quality of life by reducing seizure frequency and intensity while supporting better cognitive and emotional balance in long-term epilepsy management.